Gal-geun-dang-gwi-tang improves diabetic vascular complication in apolipoprotein E KO mice fed a western diet

BMC Complementary and Alternative Medicine

Ho Sub Lee¹  Dae Gill Kang¹  Sun Ho Shin²  Jung Joo Yoon³  Min Chul Kho³  Jung Hoon Choi⁴  Yun Jung Lee³  So Min Lee³ 

[1] Brain Korea (BK) 21 plus team, Professional Graduate School of Oriental Medicine, Wonkwang University, Iksan, Jeonbuk 540-749, Republic of Korea;Department of Internal Medicine, College of Oriental Medicine, Wonkwang University, Iksan, Republic of Korea;Hanbang Body-fluid Research Center, Wonkwang University, Iksan, Republic of Korea;Hamsoa Oriental Medical Clinic, Yeonhyang-dong, Suncheon Jeonnam 540-952, Republic of Korea

关键词: eNOS;    Insulin resistance;    Atherosclerosis;    Diabetes;    Gal-geun-dang-gwi-tang;   

Others  :  1085358
DOI  :  10.1186/1472-6882-14-453

 received in 2014-03-26, accepted in 2014-09-18,  发布年份 2014

【 摘 要 】

Background

Gal-geun-dang-gwi-tang (GGDGT), an herbal medicine, is used to treat hypertension, stroke, and other inflammatory disorders in the clinical setting. Recently, GGDGT was recognized by the Korea Institute of Oriental Medicine. This study aimed to evaluate the effects of GGDGT in a diabetic atherosclerosis model using apolipoprotein E knockout (ApoE-/-) mice fed a Western diet.

Methods

The mice were divided into four groups: control group, C57BL6J mice receiving a regular diet (RD); ApoE-/- group, ApoE-/- mice receiving a Western diet (WD); rosiglitazone group, ApoE-/- mice receiving rosiglitazone (WD + 10 mg · kg^-1 · day^-1); GGDGT group, ApoE-/- mice receiving GGDGT (WD + 200 mg · kg^-1 · day^-1).

Results

Treatment with GGDGT significantly improved glucose tolerance and plasma lipid levels. In addition, GGDGT ameliorated acetylcholine-induced vascular relaxation of the aortic rings. Immunohistochemical staining showed that GGDGT suppressed intercellular adhesion molecule (ICAM)-1 expression; however, expression of endothelial nitric oxide synthase (eNOS) and insulin receptor substrate (IRS)-1 were restored in the thoracic aorta and skeletal muscle, respectively.

Conclusions

These findings suggest that GGDGT attenuates endothelial dysfunction via improvement of the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signalling pathway and improves insulin sensitivity in diabetic atherosclerosis.

【 授权许可】

   
2014 Lee et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Haller H: Endothelial function: general considerations. Drugs 1997, 53:1-10.
• [2]Taskinen MR: Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003, 46:733-749.
• [3]Bornfeldt KE, Tabas I: Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 2011, 14:575-585.
• [4]Chen JW, Zhou SB, Tan ZM: Aspirin and pravastatin reduce lectin-like oxidized low density lipoprotein receptor-1 expression, adhesion molecules and oxidative stress in human coronary artery endothelial cells. Chin Med J (Engl) 2010, 123:1553-1556.
• [5]Maloney E, Sweet IR, Hockenbery DM, Pham M, Rizzo NO, Tateya S, Handa P, Schwartz MW, Kim F: Activation of NF-kappaB by palmitate in endothelial cells: a key role for NADPH oxidase-derived superoxide in response to TLR4 activation. Arterioscler Thromb Vasc Biol 2009, 29:1370-1375.
• [6]Boström K: Proinflammatory vascular calcification. Circ Res 2005, 96:1219-1220.
• [7]Meir KS, Leitersdorf E: Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol 2004, 24:1006-1014.
• [8]Landmesser U, Hornig B, Drexler H: Endothelial function: a critical determinant in atherosclerosis? Circulation 2004, 109:II27-II33.
• [9]Ballantyne CM: Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol 1998, 82:3Q-12Q.
• [10]Tannock LR: Advances in the management of hyperlipidemia-induced atherosclerosis. Expert Rev Cardiovasc Ther 2008, 6:369-383.
• [11]Crauwels HM, Van Hove CE, Holvoet P, Herman AG, Bult H: Plaque-associated endothelial dysfunction in apolipoprotein E-deficient mice on a regular diet: effect of human apolipoprotein AI. Cardiovasc Res 2003, 59:189-199.
• [12]Fransen P, Van Assche T, Guns PJ, Van Hove CE, De Keulenaer GW, Herman AG, Bult H: Endothelial function in aorta segments of apolipoprotein E-deficient mice before development of atherosclerotic lesions. Pflugers Arch 2008, 455:811-818.
• [13]Ito KM, Okayasu M, Koshimoto C, Shinohara A, Asada Y, Tsuchiya K, Sakamoto T, Ito K: Impairment of endothelium-dependent relaxation of aortas and pulmonary arteries from spontaneously hyperlipidemic mice (Apodemus sylvaticus). Vascul Pharmacol 2007, 47:166-173.
• [14]Namikoshi T, Tomita N, Satoh M, Haruna Y, Kobayashi S, Komai N, Sasaki T, Kashihara N: Olmesartan ameliorates renovascular injury and oxidative stress in Zucker obese rats enhanced by dietary protein. Am J Hypertens 2007, 20:1085-1091.
• [15]Kubozono T, Koike A, Nagayama O, Tajima A, Aizawa T, Fu LT, Itoh H: High diastolic blood pressure during exercise is associated with hypercholesterolemia in patients with coronary artery disease. Int Heart J 2005, 46:79-87.
• [16]Nishimatsu H, Suzuki E, Satonaka H, Takeda R, Omata M, Fujita T, Nagai R, Kitamura T, Hirata Y: Endothelial dysfunction and hypercontractility of vascular myocytes are ameliorated by fluvastatin in obese Zucker rats. Am J Physiol Heart Circ Physiol 2005, 288:H1770-H1776.
• [17]Lee YJ, Moon MK, Hwang SM, Yoon JJ, Lee SM, Seo KS, Kim JS, Kang DG, Lee HS: Anti-Inflammatory effect of Buddleja officinalis on vascular inflammation in human umbilical vein endothelial cells. Am J Chin Med 2010, 38:585-598.
• [18]Shin HK: Usugyeongheombangjip. Korea Institute of Oriental Medicine 2004, 258.
• [19]Meyrelles SS, Peotta VA, Pereira TM, Vasquez EC: Endothelial dysfunction in the apolipoprotein E-deficient mouse: insights into the influence of diet, gender and aging. Lipids Health Dis 2011, 10:211. BioMed Central Full Text
• [20]Chiu JJ, Chien S: Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev 2011, 91:327-387.
• [21]Vasquez EC, Peotta VA, Gava AL, Pereira TM, Meyrelles SS: Cardiac and vascular phenotypes in the apolipoprotein E-deficient mouse. J Biomed Sci 2012, 19:22. BioMed Central Full Text
• [22]Lee AS, Lee YJ, Lee SM, Yoon JJ, Kim JS, Kang DG, Lee HS: Portulaca oleracea ameliorates diabetic vascular inflammation and endothelial dysfunction in db/db Mice. Evid Based Complement Alternat Med 2012, 2012:741824.
• [23]Kang DG, Lee JK, Choi DH, Sohn EJ, Moon MK, Lee HS: Vascular relaxation by the methanol extract of Sorbus cortex via NO-cGMP pathway. Biol Pharm Bull 2005, 28:860-864.
• [24]Bentley MD, Rodriguez-Porcel M, Lerman A, Sarafov MH, Romero JC, Pelaez LI, Grande JP, Ritman EL, Lerman LO: Enhanced renal cortical vascularization in experimental hypercholesterolemia. Kidney Int 2002, 61:1056-1063.
• [25]Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL: ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 1994, 14:605-616.
• [26]Matsuda A, Suzuki Y, Kondo K, Ikeda Y, Umemura K: Hypercholesterolemia induces regression in neointimal thickening due to apoptosis of vascular smooth muscle cells in the hamster endothelial injury model. Cardiovasc Res 2002, 53:512-523.
• [27]Kondo T, Vicent D, Suzuma K, Yanagisawa M, King GL, Holzenberger M, Kahn CR: Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest 2003, 111:1835-1842.
• [28]Roberts CK, Barnard RJ, Sindhu RK, Jurczak M, Ehdaie A, Vaziri ND: A high-fat, refined-carbohydrate diet induces endothelial dysfunction and oxidant/antioxidant imbalance and depresses NOS protein expression. J Appl Physiol 2005, 98(1985):203-210.
• [29]Whitman SC, Miller DB, Wolfe BM, Hegele RA, Huff MW: Uptake of type III hypertriglyceridemic VLDL by macrophages is enhanced by oxidation, especially after remnant formation. Arterioscler Thromb Vasc Biol 1997, 17:1707-1715.
• [30]Gotto AM Jr: Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. Circulation 2001, 103:2213-2218.
• [31]Drexler H, Zeiher AM: Endothelial function in human coronary arteries in vivo: focus on hypercholesterolemia. Hypertension 1991, 18:II90-II99.
• [32]Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R: ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994, 14:133-140.
• [33]Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL: Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999, 104:447-457.
• [34]Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer DM III, Trocha SD, Huang PL, Smith MB, Lefer AM, Lefer DJ: Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 2001, 103:2598-2603.
• [35]King VL, Hatch NW, Chan HW, de Beer MC, de Beer FC, Tannock LR: A murine model of obesity with accelerated atherosclerosis. Obesity (Silver Spring) 2010, 18:35-41.
• [36]Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL: PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002, 40:866-871.
• [37]Nigro G, Politano L, Passamano L, Palladino A, De Luca F, Nigro G, Comi LI: Cardiac treatment in neuro-muscular diseases. Acta Myol 2006, 25:119-123.
• [38]Lee YJ, Choi DH, Kim EJ, Kim HY, Kwon TO, Kang DG, Lee HS: Hypotensive, hypolipidemic, and vascular protective effects of Morus alba L. in rats fed an atherogenic diet. Am J Chin Med 2011, 39:39-52.
• [39]Choi DH, Lee YJ, Kim JS, Kang DG, Lee HS: Cynanchum wilfordii ameliorates hypertension and endothelial dysfunction in rats fed with high fat/cholesterol diets. Immunopharmacol Immunotoxicol 2012, 34:4-11.
• [40]Voelkel NF, Tuder RM: Hypoxia-induced pulmonary vascular remodeling: a model for what human disease? J Clin Invest 2000, 106:733-738.
• [41]Cirillo P, Angri V, De Rosa S, Cali G, Petrillo G, Maresca F, D'Ascoli GL, Maietta P, Brevetti L, Chiariello M: Pro-atherothrombotic effects of leptin in human coronary endothelial cells. Thromb Haemost 2010, 103:1065-1075.
• [42]Stohr R, Federici M: Insulin resistance and atherosclerosis: convergence between metabolic pathways and inflammatory nodes. Biochem J 2013, 454:1-11.
• [43]Crissey JM, Jenkins NT, Lansford KA, Thorne PK, Bayless DS, Vieira-Potter VJ, Rector RS, Thyfault JP, Laughlin MH, Padilla J: Adipose tissue and vascular phenotypic modulation by voluntary physical activity and dietary restriction in obese insulin-resistant OLETF rats. Am J Physiol Regul Integr Comp Physiol 2014, 306:R596-R606.
• [44]Endemann DH, Schiffrin EL: Nitric oxide, oxidative excess, and vascular complications of diabetes mellitus. Curr Hypertens Rep 2004, 6:85-89.
• [45]Miike T, Kunishiro K, Kanda M, Azukizawa S, Kurahashi K, Shirahase H: Impairment of endothelium-dependent ACh-induced relaxation in aorta of diabetic db/db mice–possible dysfunction of receptor and/or receptor-G protein coupling. Naunyn Schmiedebergs Arch Pharmacol 2008, 377:401-410.
• [46]Takase H, Moreau P, Küng CF, Nava E, Lüscher TF: Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency: effect of verapamil and trandolapril. Hypertension 1996, 27:25-31.
• [47]Gervais M, Pons S, Nicoletti A, Cosson C, Giudicelli JF, Richer C: Fluvastatin prevents renal dysfunction and vascular NO deficit in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003, 23:183-189.
• [48]von Eckardstein A, Nofer JR, Assmann G: High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001, 21:13-27.
• [49]Sasakawa T, Sasakawa Y, Masunaga T, Fujitsu T, Hirayama Y, Ohkubo Y, Mutoh S: FK506 suppresses E-selectin, ICAM-1 and VCAM-1 expression on vascular endothelial cells by inhibiting tumor necrosis factor alpha secretion from peripheral blood mononuclear cells. Cytokine 2005, 29:67-71.
• [50]Rexrode KM, Manson JE, Hennekens CH: Obesity and cardiovascular disease. Curr Opin Cardiol 1996, 11:490-495.
• [51]Zhang CM, Chen XH, Wang B, Liu F, Chi X, Tong ML, Ni YH, Chen RH, Guo XR: Over-expression of NYGGF4 inhibits glucose transport in 3 T3-L1 adipocytes via attenuated phosphorylation of IRS-1 and Akt. Acta Pharmacol Sin 2009, 30:120-124.
• [52]Wu WL, Gan WH, Tong ML, Li XL, Dai JZ, Zhang CM, Guo XR: Over-expression of NYGGF4 (PID1) inhibits glucose transport in skeletal myotubes by blocking the IRS1/PI3K/AKT insulin pathway. Mol Genet Metab 2011, 102:374-377.
• [53]Matsuda S, Kobayashi M, Kitagishi Y: Roles for PI3K/AKT/PTEN pathway in cell signaling of nonalcoholic fatty liver disease. ISRN Endocrinol 2013, 2013:472432.
• [54]Rask-Madsen C, Buonomo E, Li Q, Park K, Clermont AC, Yerokun O, Rekhter M, King GL: Hyperinsulinemia does not change atherosclerosis development in apolipoprotein E null mice. Arterioscler Thromb Vasc Biol 2012, 32:1124-1131.